全文获取类型
收费全文 | 383篇 |
免费 | 23篇 |
国内免费 | 10篇 |
专业分类
基础医学 | 24篇 |
临床医学 | 43篇 |
内科学 | 149篇 |
特种医学 | 9篇 |
外科学 | 7篇 |
综合类 | 56篇 |
预防医学 | 6篇 |
药学 | 98篇 |
中国医学 | 22篇 |
肿瘤学 | 2篇 |
出版年
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 5篇 |
2017年 | 7篇 |
2016年 | 16篇 |
2015年 | 19篇 |
2014年 | 38篇 |
2013年 | 47篇 |
2012年 | 40篇 |
2011年 | 51篇 |
2010年 | 34篇 |
2009年 | 29篇 |
2008年 | 33篇 |
2007年 | 27篇 |
2006年 | 16篇 |
2005年 | 13篇 |
2004年 | 16篇 |
2003年 | 6篇 |
2002年 | 1篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 1篇 |
排序方式: 共有416条查询结果,搜索用时 31 毫秒
41.
42.
43.
An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B
下载免费PDF全文
![点击此处可从《Liver international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
44.
A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial 总被引:2,自引:0,他引:2
ADHOC International Steering Committee 《HIV medicine》2002,3(4):229-238
Objectives
To assess the efficacy and safety of adefovir dipivoxil (ADV) added to stable background antiretroviral therapy (ART) in HIV‐infected individuals with advanced HIV disease.Methods
ADHOC was a randomized, double‐blind, placebo‐controlled, international multicentre trial. Three hundred and one individuals with CD4 cell counts < 100 cells/μL or < 200 cells/μL with nadir < 50 cells/μL were allocated to receive either 120 mg ADV (subsequently 60 mg) (n = 161) or matching placebo (n = 140) once daily.Results
Over a median follow‐up of 76 weeks, 23 (14%) and 18 (13%) participants assigned ADV and placebo, respectively, developed a new AIDS event or died (hazard ratio = 1.23, 95% confidence interval 0.66–2.29, P= 0.51). There was a lower incidence of new or recurrent herpes events in the ADV group (P = 0.009). The mean increase in CD4 cell count from baseline to week 24 was 23.0 and 24.4 cells/µL in ADV and placebo groups, respectively (P = 0.89), and the mean decrease in RNA was 0.32 and 0.35 log10 copies/mL at week 24 (P = 0.87) in a subset of participants. There was greater weight loss in the ADV group during the trial (P = 0.007). One hundred and twenty‐four participants (41%) had stable background ART in the 8 weeks prior to and the 24 weeks after randomization. There was no significant imbalance in background ART regimens between the two treatment groups. Ninety‐seven serious adverse events (SAEs) occurred, 65 and 32 in the ADV and placebo groups, respectively, with significantly shorter time to first SAE in the ADV group (P = 0.002). A total of 33 participants developed proximal renal tubular dysfunction during the trial, all but one in the ADV group.Conclusions
Due to the early termination of recruitment, ADHOC was unable to assess the original objective of clinical disease progression. Adding ADV to background antiretroviral therapy in advanced HIV disease did not provide immunological or virological improvement compared with placebo. Furthermore, at the doses used in this trial, ADV was associated with a significantly higher incidence of SAEs.45.
Several nucleoside analogues (penciclovir, lobucavir, dioxalane guanine [DXG], 1-β-2,6-diaminopurine dioxalane [DAPD], L-FMAU, lamivudine) and acyclic nucleoside phosphonate analogues (adefovir, tenofovir) that are in clinical use, in clinical trials or under preclinical development for the treatment of hepatitis B virus (HBV) infections, were evaluated for their inhibitory effect on the replication of a la- mivudine-resistant HBV variant containing the methionine → valine substitution (M550V) in the polymerase nucleoside-binding domain. The antiviral activity was determined in the tetracycline-responsive HepAD38 and HepAD79 cells, which are stably transfected with either a cDNA copy of the wild-type pregenomic RNA or with cDNA containing the M550V mutation. As expected, lamivudine was much less (≈ 200-fold) effective at inhibiting replication of the M550V mutant virus than the wild-type virus. In contrast, adefovir, tenofovir, lobucavir, L-FMAU, DXG and DAPD proved almost equally effective against both viruses. A second objective of this study was to directly compare the antiviral potency of the anti-HBV agents in HepG2 2.2.15 cells (which are routinely used for anti-HBV drug-screening purposes) with that in HepAD38 cells. HepAD38 cells produce much larger quantities of HBV than HepG2 2.2.15 cells, and thus allow drug screening in a multiwell plate format. All compounds were found to be almost equally effective at inhibiting HBV replication in HepAD38 cells (as in HepG2 2.2.15 cells), except for penciclovir, which was clearly less effective in HepAD38 cells. 相似文献
46.
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. 总被引:45,自引:0,他引:45
Yun-Fan Liaw Nancy Leung Richard Guan George K K Lau Ismail Merican Geoff McCaughan Edward Gane Jia-Horng Kao Masao Omata 《Liver international》2005,25(3):472-489
BACKGROUND/AIMS: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update. METHODS: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL. RESULTS: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested. CONCLUSION: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment. 相似文献
47.
Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B(CHB). The objective of the present study was to compare the efficacy and safety of pegylated interferon(Peg-IFN) alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone(1.5 μg/kg once weekly) or Peg-IFN alpha-2b plus adefovir(10 mg daily) for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30(36.7%) patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31(25.8%) in the monotherapy group(P=0.36). In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group(76.7% vs. 29.0%, P〈0.001). Thyroid dysfunction was more frequent in the combination group than in the monotherapy group(P〈0.05). In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function. 相似文献
48.
目的 探讨阿德福韦酯相关性Fanconi综合征继发低磷性骨软化症的临床特点。方法 报道4例阿德福韦酯相关性Fanconi综合征继发低磷性骨软化症,并进行相关文献复习,总结其临床特点。结果 4例患者均表现为不同程度骨关节疼痛、肌无力,既往乙肝病史,服用阿德福韦酯抗病毒治疗3~6年不等,血液检查示低血磷,同时合并不同程度低血钾、低血尿酸,尿检示糖尿及蛋白尿,诊断为阿德福韦酯相关性Fanconi综合征并继发低磷性骨软化症。复习文献发现,阿德福韦酯治疗所致Fanconi综合征继发低磷性骨软化症有剂量、时间依赖性及可逆性特点,应用小剂量阿德福韦酯(10 mg/d)后出现Fanconi综合征多见于亚裔男性。患者常因骨关节疼痛起病,首诊科室多为骨科及风湿科,确诊周期长,易漏诊、误诊。结论 凡服用阿德福韦酯的患者,无论剂量大小,均应定期进行相关检查,如血钙、血磷、尿常规与尿生化等,以监测是否发生Fanconi综合征并继发低磷性骨软化症。 相似文献
49.
U. Herbers S. Amini‐Bavil‐Olyaee A. Mueller T. Luedde C. Trautwein F. Tacke 《Journal of viral hepatitis》2013,20(2):141-148
Summary. Hepatitis B e antigen (HBeAg) negative hepatitis B virus (HBV) infections caused by precore (PC) or basal core promoter (BCP) mutations are associated with disease progression and complications. PC or BCP mutations may enhance the replication capacity of distinct drug‐resistance‐associated polymerase mutations, but their effect on adefovir‐resistant HBV mutants is unclear. Importantly, BCP mutations were an independent risk factor for virological breakthrough in lamivudine‐resistant patients treated with adefovir. We aimed at addressing the functional consequences of PC and BCP mutations on the replication and drug susceptibility of adefovir‐resistant HBV mutants. Therefore, HBV constructs with wild type (WT) or adefovir‐resistant rtN236T, rtA181V and rtA181T mutations, with or without concomitant PC or BCP mutations, were analysed in vitro using molecular assays. The adefovir‐resistant polymerase mutations rtN236T, rtA181V and rtA181T showed a drastically reduced viral replication compared with WT. Interestingly, additional PC or BCP mutations enhanced the reduced replication efficacy of adefovir‐resistant constructs and restored HBV replication to WT level. HBV rtA181T mutants displayed abolished hepatitis B surface antigen (HBsAg) secretion, owing to a sW172* stop codon in the overlapping envelope gene. All rtN236T‐ or rtA181V/T‐containing constructs, regardless of concomitant PC or BCP mutations, were resistant to adefovir, but remained susceptible to telbivudine, entecavir and tenofovir. In conclusion, adefovir drug resistance mutations reduced viral replication, which can be significantly increased by additional HBeAg‐suppressing PC or BCP mutations. Because increased HBV replication in HBeAg‐negative patients has been associated with an unfavourable clinical course, close monitoring appears indispensable during adefovir treatment in HBeAg‐negative patients. 相似文献
50.